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Figure S1 
(A) Relative expression of individual miR-17-92 miRNAs in MYCN amplified tumours (A), 
MYCN single copy high-risk tumours (SH) and MYCN single copy low risk tumours (SL) 
(dataset D1, supplemental table 1). Significant differential expression (Mann Whitney, p < 
0.05) is indicated (*) (whiskers: Tukey). (B) Kaplan Meier plots for overall survival (OS) 
based on the pathway activity score of individual miR-17-92 miRNAs, represented as 
quartiles (dataset D1, supplemental table 1). Increased activity of each individual member 
form the miR-17-92 cluster is proportionally correlated to a poor overall survival. 
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Figure S2 
(A) Relative expression of miR-17-92 miRNAs upon treatment of SHEP-TR-miR-17-92 cells 
with tetracycline (mean ± SEM). (B) Protein quantification using LC/MS-MS. Histogram 
showing the number of quantified peptides per protein. (C) Histogram showing the 
distribution of protein fold changes of proteins that were quantified by at least 2 peptides. 
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Figure S3 
(A) Fraction of proteins containing at least one 7mer-8mer miR-17-92 site (black) of one 
6mer-7mer-8mer miR-17-92 site (grey) in function of the protein fold change (grouped in 6 
different bins according to fold change). Only downregulated proteins are shown. Dashed 
horizontal lines indicate the background miR-17-92 site occurrence (determined as the 
fraction of unchanged proteins harboring at least one 7mer-8mer miR-17-92 site of one 6mer-
7mer-8mer miR-17-92 site). (B) Average number of 3’UTR miR-17-92 sites per protein in 
function of the protein fold change. Dashed lines indicate background measurement 
(calculated as in (A)). (C) Average number of miR-17-92 sites per nucleotide in function of 
protein fold change for 3’UTR sites (red), 5’UTR sites (blue) and coding sequence sites 
(CDS) (green). (D) Average fold change ± SEM of proteins for which the transcripts contain 
at least one 8mer miR-17-92 site in the 3’UTR (red), 5’UTR (blue) and CDS (green). (E) 
Number of co-occurring miR-17-92 sites in the 3’UTR of transcripts from downregulated 
proteins. The X-axis indicates the number of co-occurring sites between the miRNA listed on 
top of each graph and the miRNAs listed below each bar (miR-17/miR-20a and miR-
19a/miR-19b) are analyzed together as they share identical seeds. The first bar of each graph 
represents the number downregulated proteins that only have one (or more) sites for the 
respective miRNA. Significant co-occurrence was determined by comparing results for 
downregulated proteins to results for a reference set (upregulated proteins) using Fisher’s 
Exact test (p < 0.05). 
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Figure S4 
Gene set enrichment analysis plots for gene sets enriched among the proteins, upregulated 
upon miR-17-92 activation.  
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Figure S5 
Relative mRNA expression (mean ± SEM) of TGFβ-responsive genes upon TET treatment of 
SHEP-TR-miR-17-92 cells. 
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Figure S6 
(A) Correlation clustering between miR-17-92 miRNA expression and TGFβ target gene 
expression in 40 primary neuroblastoma tumors (dataset D3, supplemental table 1). The 
heatmap indicates the Spearman’s rank rho value. TGFβ target genes are indicated by the grey 
sidebar, miR-17-92 miRNAs are indicated by the black sidebar. (B) Heatmap showing 
relative expression of TGFβ-pathway components and target genes in neuroblastoma SHEP 
cells transfected with a scrambled control or with pre-miRs for the individual miR-17-92 
miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a and miR-92a). Black dots mark 
genes that have at least one 3’UTR 7mer site for the corresponding miRNA.   
A 
 
 
B 
Mestdagh et al. 
 
 
 
 
 
 
 
 
Mestdagh et al. 
Figure S7 
Model for miR-17-92 mediated TGFβ pathway repression. 
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Document S2. rdml-file for RT-qPCR expression profiling of 430 miRNAs of 
SHEP-TR-miR-17-92 cells treated with tetracycline for 72h, provided as a 
separate file. 
 
Table S1. Overview of mRNA and miRNA expression datasets  
Data set ID samples mRNA miRNA reference 
D1 95  X (Mestdagh et al., 2009a)
D2 251 X  (Oberthuer et al., 2006) 
D3 40 X X (Mestdagh et al., 2009a)
 
Table S2. Expression fold change and miR-17-92 seed frequency of all reliably 
measured proteins 
This table is provided as a separate file. 
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Table S3. miR-17-92 seed occurrence and protein fold change for TGFB-target 
genes downregulated upon miR-17-92 activation 
protein 3’UTR seed(s) fold change (log2) 
SERPINE1 miR-17/miR-20a miR-19a/miR-19b -1.93 
THBS1 miR-18a miR-19a/miR-19b -1.05 
ITGA4 miR-17/miR-20a miR-19a/miR-19b -0.989 
FNDC3B miR-17-92 -0.972 
JUP none -0.869 
PPP1R13L miR-19a/miR-19b -0.813 
FILIP1L miR-17/miR-20a -0.735 
ICAM1 miR-92a -0.689 
EPHA2 none -0.603 
COL1A1 none -0.546 
CDKN1A miR-17/miR-20a -0.546 
PFKFB3 miR-17/miR-20a miR-19a/miR-19b -0.544 
CTNNA1 miR-18a -0.522 
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Table S4. List of peptide quantifications from the forward experiment. 
This table is provided as a separate file. Peptides are ordered on SwissProt accession number 
and increasing start position. Columns from left to right contain the SwissProt accession 
number, sequence of the identified peptide, start and end position of the peptide in the protein 
sequence, MASCOT score and threshold of the identified light (L) and/or heavy (H) 
component of the peptide, the L/H peptide ratio, the protein name and the L/H protein ratio. 
Table S5. List of peptide quantifications from the reverse experiment. 
This table is provided as a separate file. Peptides are ordered on SwissProt accession number 
and increasing start position. Columns from left to right contain the SwissProt accession 
number, sequence of the identified peptide, start and end position of the peptide in the protein 
sequence, MASCOT score and threshold of the identified light (L) and/or heavy (H) 
component of the peptide, the L/H peptide ratio, the protein name and the L/H protein ratio. 
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Supplemental Experimental Procedures 
COFRADIC analysis 
To reduce arginine to proline conversion and thus dilution of the 13C-label, the arginine 
concentration was lowered to 30% of its normal concentration in DMEM. Cell cultures were 
then treated with tetracycline for 72 hours to induce miR-17-92 expression. A biological 
replicate was created by swapped labeling. Cells were harvested by Versene-EDTA and 
washed with PBS. Cell pellets were frozen at -80ºC until further use. Prior to proteome 
analysis, cells were lysed in 250 µl lysis buffer containing 0.8% CHAPS in 50 mM HEPES 
(pH 7.4), 100 mM NaCl and 0.5 mM EDTA supplemented with protease inhibitors (Complete 
Protease inhibitor cocktail tablet (Roche, Basel, Switzerland); one tablet per 100 ml buffer)) 
for 20 minutes on ice. Cell debris was removed by centrifugation for 15 min at 16,000g at 4ºC 
after which the protein concentration was measured using the Biorad Protein Assay. Then, 
equal amounts of both proteome preparations (i.e. from differently labeled control cells or 
cells in which miR-17-92 expression was induced) were mixed together. To denature proteins, 
solid guanidinium hydrochloride was added to a final concentration of 4 M (the total sample 
volume was 1 ml). Proteins were then reduced and S-alkylated for 60 minutes at 30ºC by 
adding tris(2-carboxyethyl) phosphine and iodoacetamide to final concentrations of 3 mM and 
6 mM respectively. Half of each proteome sample was then desalted on a NAP-5 column in 1 
ml of 20 mM triethylamonium bicarbonate (pH 8.0). These desalted protein mixtures were 
heated for 5 min at 95°C, put on ice for 5 min, after which trypsin (sequencing grade, 
modified porcine trypsin, Promega Corporation, Madison, WI, USA) was added to a 
trypsin/substrate ratio of 1/50 (w/w). Trypsin digestion proceeded overnight at 37°C after 
which the sample was dried in vacuo. Dried peptides were then re-dissolved in 105 µl of 
solvent A (10 mM ammonium acetate (pH 5.5) in water/acetonitrile (98/2 (v/v), both Baker 
HPLC analysed, Mallinckrodt Baker B.V., Deventer, The Netherlands)) and 100 µl of this 
peptide mixture was used to isolate methionine-containing peptides by the COFRADIC 
technology as described previously (Gevaert et al., 2002). In this way, the complexity of the 
peptide mixture was reduced by a factor of about five and the hence isolated peptide mixture 
– which is highly enriched for methionine-containing peptides – were analyzed by LC-
MS/MS using an Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) that 
was operated as previously described (Ghesquiere et al., 2009). 
Generated MS/MS spectra were converted to MS/MS peak lists as described (Ghesquiere et 
al., 2009) and these peak lists were searched in the human fraction of the Swiss-Prot database 
(version 56.4, containing 20,408 human protein sequences) using a locally installed version of 
the MASCOT database search engine (version 2.2.04 (Perkins et al., 1999)). 
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Carbamidomethylation of cysteine and oxidation of methionine were set as fixed MASCOT 
parameters, and acetylation of a protein’s N-terminus, pyro-carbamidomethyl cysteine (from 
N-term cysteine), pyroglutamate formation (N-term glutamine) were considered as variable 
modifications. Trypsin/P was set as the protease with one missed cleavage allowed and 
MASCOT’s quantitation parameters were set to SILAC Arg and Lys + 6. Only peptide 
identifications that were ranked one, scored above the corresponding MASCOT threshold 
score for identity set at 99% confidence were considered identified. The false discovery rate 
of these identifications was determined according to the method described by Elias and Gygi 
(Elias and Gygi, 2007) and found to be 0.21% (on the spectrum level). Quantification of the 
identified peptides was then done using MASCOT Distiller Quantitation Toolbox 
(www.matrixscience .com) in the ‘precursor’ mode. The software tried to fit an ideal isotopic 
distribution on the experimental data based on the peptide average amino acid composition. 
This was followed by extraction of the XIC signal of both peptide components (light and 
heavy) from the raw data. Ratios were calculated from the area below the light and heavy 
isotopic envelope of the corresponding peptide (integration method ‘trapezium’, integration 
source ‘survey’). To calculate this ratio value, a least squares fit to the component intensities 
from the different scans in the XIC peak was created. MS scans used for this ratio calculation 
were situated in the elution peak of the precursor determined by the Distiller software (XIC 
threshold 0.3, XIC smooth 1, Max XIC width 250). To validate the calculated ratio, the 
standard error on the least square fit had to be below 0.14 and correlation coefficient of the 
isotopic envelope needed to be above 0.90. The number of recorded and identified spectra as 
well as the number of unique peptide quantifications is indicated for both analyses in the table 
below. All identified spectra are made publically available in the PRIDE database 
(www.ebi.ac.uk/pride), accession 14860. 
analysis 
# MS/MS spectra 
recorded 
# MS/MS spectra 
identified 
# unique peptide 
quantifications 
forward 83275 30141 14524 
reversed 127760 32833 15875 
 
Next, protein ratios were calculated as the average of individual peptide ratios by the in-house 
developed Rover algorithm (Colaert et al., 2010). Peptide ratios that could not be adequately 
calculated by the Distiller software were also manually validated using the Rover application 
(typically belonging to highly regulated peptides and proteins). Supplemental tables 4 and 5 
show the Rover output and contain all peptide quantifications for the forward and reversed 
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experiment. In case a peptide could be derived from more than one protein sequence, all 
protein isoforms are listed which explains why the number of peptide quantifications in these 
lists exceeds the number of unique peptide quantifications in the table above.  Peptide ratios 
of the repeated experiments were averaged and proteins that were quantified by at least 2 
peptides were selected for further analysis. UniProtKB accessions were mapped to RefSeq 
IDs using the Biomart tool from Ensembl (www.ensembl.org). 
RT-qPCR 
2 µg of RNA from each sample was treated with RQ1 DNase I (Promega) and desalted using 
a Microcon-100 spin column (Millipore). cDNA synthesis was performed on the eluate with 
the iScript cDNA synthesis kit (Bio-Rad). All manipulations were conducted according to the 
manufacturer’s instructions. First strand cDNA was diluted to a final concentration of 5 ng/µl 
(total RNA equivalent). RT-PCR amplification reactions were carried out in a total volume of 
7.5 µl, containing 10 ng of template cDNA, 3.75 µl of 2x SYBR Green I reaction mix 
(Eurogentec), 1 µl nuclease-free water (Sigma) and 0.375 µl of a 5 µM solution of each 
primer.  Cycling conditions were as follows: 10 min at 95°C followed by 45 cycles of 
denaturation (10s at 95°C) and elongation (45s at 60°C). All reactions were performed on a 
LightCycler 480 (Roche). Primers were designed using Primer3 (Rozen and Skaletsky, 2000) 
and validated through RTPimerDB’s in silico assay evaluation pipeline (Lefever et al., 2009). 
Raw Cq values were imported into qbaseplus (Hellemans et al., 2007) (www.biogazelle.com) 
and normalized using a selection of stably expressed reference genes (UBC, SDHA, GAPDH 
and Alu-sx). Primer sequences for UBC, SDHA and GAPDH are available in the public 
RTprimerDB database (http://www.rtprimerdb.org/) (gene (RTPrimerDB-ID): UBC(8), 
SDHA(7), GAPDH(3)). For Alu-sx, the following primer sequences were used: F: 
TGGTGAAACCCCGTCTCTACTAA, R: CCTCAGCCTCCCGAGTAGCT. 
miRNA expression profiling and data normalization were performed as described previously 
(Mestdagh et al., 2008; Mestdagh et al., 2009b). 
 
Pre-miR transfection 
Individual pre-miR molecules (Ambion) were transfected in neuroblastoma SHEP-cells at a 
concentration of 100 nM using Xtremegene transfection reagent (Roche) according to the 
manufacturer’s instructions. Pre-miR negative control #1 (Ambion) was used as a scrambled 
control. Transfection efficiency was monitored by flow cytometry using a fluorescently 
labeled pre-miR (Ambion) and estimated to be 80% or higher. Cells were cultured in RPMI 
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(Invitrogen), 10% FCS in the absence of antibiotics. Cells were harvested for RNA isolation 
(miRNeasy, Qiagen) 24h post transfection. 
 
3’UTR luciferase constructs 
3’UTR luciferase reporter constructs for TGFBR2 were obtained from Switchgear Genomics. 
For SMAD2 and SMAD4, 74 bp oligonucleotides spanning the predicted 3’UTR miRNA 
binding site and flanked by XhoI and NotI restriction sites were cloned into psicheck2 
(Promega) as described previously (Cloonan et al., 2008). The following oligonucleotides 
were used: 
SMAD2_miR-18a_F 
TCGAGAAAACAGCACTTGAGGTCTCATCAATTAAAGCACCTTGTGGAATCTGTTT
CCTATATTTGAATATTAGC 
SMAD2_miR-18a_R 
GGCCGCTAATATTCAAATATAGGAAACAGATTCCACAAGGTGCTTTAATTGATGA
GACCTCAAGTGCTGTTTTC 
SMAD2_miR-19_F 
TCGAGCCTTCCTCAACCTTTGCTGTAAAAATTTCATTTGCACCACATCAGTACTA
CTTAATTTAACAAGCTTGC 
 
 
SMAD2_miR-19_R 
GGCCGCAAGCTTGTTAAATTAAGTAGTACTGATGTGGTGCAAATGAAATTTTTAC
AGCAAAGGTTGAGGAAGGC 
SMAD2_miR-92a_F 
TCGAGTTTTTTTCTCTGATGGCATTAACTTTGTAATGCAATATGATGGATGCAGAC
CCTGTTCTTGTTTCCCGC 
SMAD2_miR-92a_R 
GGCCGCGGGAAACAAGAACAGGGTCTGCATCCATCATATTGCATTACAAAGTTA
ATGCCATCAGAGAAAAAAAC 
SMAD4_miR-18a_F 
TCGAGAAGACTTAATTTTAACCAAAGGCCTAGCACCACCTTAGGGGCTGCAATA
AACACTTAACGCGCGCACGC 
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SMAD4_miR-18a_R 
GGCCGCGTGCGCGCGTTAAGTGTTTATTGCAGCCCCTAAGGTGGTGCTAGGCCTT
TGGTTAAAATTAAGTCTTC 
SMAD4_ miR-19_miR-17/20_ F 
TCGAGGTTTGATTTTTAAGATTTTTTTTTTCTTTTGCACTTTTGAGTCCAATCTCA
GTGATGAGGTACCTTCGC 
SMAD4_ miR-19_miR-17/20_ R 
GGCCGCGAAGGTACCTCATCACTGAGATTGGACTCAAAAGTGCAAAAGAAAAAA
AAAATCTTAAAAATCAAACC 
SMAD2_miR-18a_mut_F 
TCGAGAAAACAGCACTTGAGGTCTCATCAATTAAATCCAATTGTGGAATCTGTTT
CCTATATTTGAATATTAGC 
SMAD2_miR-18a_mut_R 
GGCCGCTAATATTCAAATATAGGAAACAGATTCCACAATTGGATTTAATTGATGA
GACCTCAAGTGCTGTTTTC 
SMAD4_miR-18a_mut_F 
TCGAGAAGACTTAATTTTAACCAAAGGCCTAGCACTACTTTCGGGGCTGCAATA
AACACTTAACGCGCGCACGC 
 
SMAD4_miR-18a_mut_R 
GGCCGCGTGCGCGCGTTAAGTGTTTATTGCAGCCCCGAAAGTAGTGCTAGGCCTT
TGGTTAAAATTAAGTCTTC 
 
For TGFBR2, miRNA binding sites were mutated using the Quickchange site-directed 
mutagenesis kit (Agilent) according to the manufacturer’s instructions. The following primers 
were used: 
TGFBR2_miR-17/20_1_F 
GATTGATTTTTACAATAGCCAATAACATTTTCCAGTTATTAATGCCTGTATATAAA
TATGAATAGCTA 
TGFBR2_miR-17/20_1_R 
TAGCTATTCATATTTATATACAGGCATTAATAACTGGAAAATGTTATTGGCTATTG
TAAAAATCAATC 
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TGFBR2_miR-17/20_2_F 
GGTCAGCACAGCGTTTCAAAAAGTGAAGCAAAGGTATAAATATTTGGAGATTTTG
CAGGAAAA 
TGFBR2_miR-17/20_2_R 
TTTTCCTGCAAAATCTCCAAATATTTATACCTTTGCTTCACTTTTTGAAACGCTGTG
CTGACC 
 
miRNA target site analysis 
Four miRNA seed types were considered for miRNA target site analyses: 6mer, 7mer-A1, 
7mer-m8 and 8mer sites (Grimson et al., 2007). Target sites were identified using a custom 
Perl script. 5’ UTR, CDS and 3’UTR sequences were taken from Baek et al. (Baek et al., 
2008).  
 
 
 
Candidate miR-17-92 target gene selection 
Genes with a protein expression fold change below -0.5 (log2) and at least one 3’ UTR miR-
17-92 site were selected as candidate miR-17-92 target genes. The expression fold change 
cutoff of 0.5 was selected as the fold change that deviated from the linear fit in a normal QQ-
plot. Throughout the manuscript, downregulated proteins are defined by a log2 expression 
fold change < -0.5, upregulated proteins by a log2 expression fold change > 0.5. 
 
Xenografts 
SHEP-TR-miR-17-92 and SHEP-TR (control) cells were transfected with a luciferase 
expressing mammalian vector. This vector was obtained by cloning the firefly luciferase gene 
under the control of a CMV promoter and enables bioluminescent imaging of viable cells in 
vivo. Stable clones obtained after 15 days of selection in 300ug/ml hygromicine (Sigma, 
USA) were evaluated for their bioluminescence signal by serial cellular dilutions incubated 
with the luciferine substrate. The bioluminescence signal was acquired by an IVIS illumina 
3D Imaging System (Xenogen Corp. Alameda, CA). Etherotopic xenografts were established 
in atymic nude mice (n=5) by injection of 106 SHEP-TR cells subcutaneosly in the left 
flanking site and 106 SHEP-TR-miR-17-92 cells in the rigth flanking site of each individual 
animal. Mice were fed with tetracycline (from SIGMA) once a day using oral gavage prestige 
200ul (2mg/ml in ddH2O). In vivo tumorigenic bioluminiscence imaging was performed by 
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measuring bioluminescence (BLI, phothon/sec) of luciferine positive living cells at 0, 7, 14 
and 21 days post injection, measuring the median value of emissions from three scans per 
animal at each flanking site. 
 
Immunohistochemistry and Western blot 
SHEP-TR-miR-17-92 cells, tetracycline treated or untreated, were stimulated with TGFβ1 for 
4 h. After harvesting, 200 μl of cell suspension were centrifuged on a cytospin glass using a 
cytospin chamber. The cytopreparations were air dried, fixed with 4% paraformaldehyde 
(Sigma Aldrich, Munich, Germany) for 10 min followed by 45 min in Tris-1% Triton buffer. 
After antigen retrieval, pSMAD2 immunoreactivity (anti-pSMAD2, Cell Signaling) was 
detected using the Dako Auto-stainer Plus (Glostrup, Denmark) and the Dako EnVision Flex 
system (Glostrup, Denmark) according to the manufacturer´s instructions. For Western blot 
analysis, cells were lysed in RIPA buffer, separated on a SDS–PAGE gel and blotted onto 
Immobilon-P (Millipore, Bedford, MA, USA) membrane. The membrane was incubated with 
anti-phosphorylated SMAD2 (pSMAD2, Cell Signaling Technology) or anti-ACTIN (ICN 
Biomedicals, Aurora, OH, USA). HRP-conjugated secondary antibodies were obtained from 
Amersham Biosciences. Proteins were detected by Super Signal chemiluminescence substrate 
(Pierce, Rockford, IL, USA). Images were processed using ImageJ software. 
 
Statistics 
All statistical analyses were performed using R Bioconductor software. For survival analysis, 
rank-based pathway scores were calculated as described previously (Fredlund et al., 2008; 
Mestdagh et al., 2009a). Samples (n) were ranked according to the expression level of each 
gene/miRNA within the set and rank scores (ranging from 1 to n) were assigned. This was 
repeated for each gene in the gene set. Next, rank scores were summed generating an activity 
score of the gene/miRNA set for each sample. Kaplan-Meier analysis was performed using 
pathway activity score quartiles. 
MiRNA target site overrepresentation was evaluated using Fisher’s Exact test in combination 
with Bonferroni multiple testing correction. Differential expression/activity was evaluated 
using the Mann-Whitney test, unless stated otherwise. 
For the identification of relevant biological pathways among the up- and down-regulated 
proteins, a gene list ranked according to protein expression was analyzed using GSEA with 
the chemical and genetic perturbations collection (Subramanian et al., 2005). Gene lists with a 
false discovery rate (FDR) below 5% were considered significant. For calculation of 
individual miR-17-92 miRNA contributions to the significant gene lists the contributing genes 
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of each gene list were analyzed for the presence of 7mer and 8mer miR-17-92 sites. For each 
gene list, the fraction of targets per individual miR-17-92 miRNA was calculated. Data was 
log transformed and standardized before hierarchical clustering (method: Ward, distance: 
Manhattan). Gene lists with two or more missing values were excluded for clustering 
purposes.  
Cell adhesion and proliferation assays 
To evaluate cell adhesion, ells were quickly washed in Versene and then incubated at 37°C in 
the presence of Versene. After 15 min, the cells were visualized under a microscope to assure 
that the cell-cell contacts were disrupted. The cells were then counted, centrifuged and 
suspended in medium (RPMI, 10% FCS) at a concentration of 2x106 cells/ml and thereafter 
incubated on a rotating platform at 37°C for 1 h and then analyzed. Each treatment was 
assayed in triplicate and repeated three times. Pictures were processed using ImageJ software. 
For cell proliferation, SHEP-TR-miR-17-92 cells were trypsinized and seeded in 96-well 
xCELLigence E-plates (Roche) (10000 cells/well) according to the manufacturer’s 
instructions. After 24 h, cells were either treated with tetracycline or left untreated and were 
monitored in real-time on the xCELLigence system. Five replicate measurements per 
condition were obtained. SMAD2/SMAD4 overexpression For overexpression of SMAD2 
and SMAD4 SHEP-TR-miR-17-92 cells were seeded in 6-well plates 12 hours prior to 
transfection at a density of 100,000 cells per well. The cells were then transfected with either 
pFLAG-SMAD2, pFLAG-SMAD4 (400 ng/well, respectively) and pEGFP-C1 (Clontech, 
USA) vectors (200 ng/well) or control pHA-CMV (Clontech, USA) (800 ng/well) and 
pEGFP-C1 vectors (200 ng/well) using Lipofectamine transfection reagent in OptiMEM I 
Reduced Serum Medium. The cells were thereafter grown for 48 hours in RPMI (Invitrogen) 
supplemented with fetal calf serum (1%) tetracycline containing medium. GFP transfection 
and total cell count was assessed using the Nucleocounter 3000 system (Chemotek, 
Denmark). 
 
 
CAGA-Luciferase reporter assay 
For luciferase experiments, tetracycline or control treated SHEP-TR-miR-17-92 cells were 
seeded in 96-well plates 12 hours prior to transfection at a density of 10000 cells per well. 
The cells were then transfected with the (CAGA)12-Luc luciferase reporter  vector containing 
twelve CAGA SMAD binding sites (Dennler et al., 1998) (400 ng/well) using Lipofectamine 
2000 transfection reagent in OptiMEM I Reduced Serum Medium. Following transfection, 
cells were treated as indicated in the figure legends. Cells were lysed and assayed for 
luciferase and renilla activity using the Dual-Luciferase Reporter Assay System (Promega, 
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Madison, WI, USA) and a TD-20/20 Luminometer (Turner Biosystems, Sunnyvale, CA, 
USA). 
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